In the future, the accumulation of such structural studies with other anti-CTLA-4 antibodies can enhance the understanding of the mechanism related to the therapeutic efficacy of anti-CTLA-4 antibodies in cancer immunotherapy. Here, CTLA4 is linked to cancer.